“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Core Insights - BriaCell Therapeutics Corp.'s Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been highlighted in Nature Medicine's Year In Review as a significant trial to watch in 2026 [1][8] Group 1: Clinical Trial Details - The BRIA-ABC trial aims to evaluate the effectiveness of Bria-IMT, a new cell-based immunotherapy, in improving outcomes for patients with metastatic breast cancer who have undergone multiple prior treatments [2][3] - The trial is inclusive, allowing participation from individuals with all breast cancer subtypes, including those with brain metastases and extensive prior treatments [2] - BriaCell has screened over 230 patients and enrolled more than 160 patients to date, with interim data analysis planned once 144 patient events occur [4] Group 2: Regulatory and Market Implications - Positive results from the Phase 3 study could lead to full approval and marketing authorization of Bria-IMT for metastatic breast cancer patients [4] - The Bria-IMT combination regimen has received FDA Fast Track designation, which may expedite its development and review process [4]